Acceptability of Psychotherapy, Pharmacotherapy, and Self-Directed Therapies in Australians Living with Chronic Hepatitis C
- 275 Downloads
Despite the prevalence of psychiatric co-morbidity in chronic hepatitis C (CHC), treatment is under-researched. Patient preferences are likely to affect treatment uptake, adherence, and success. Thus, the acceptability of psychological supports was explored. A postal survey of Australian CHC outpatients of the Royal Adelaide Hospital and online survey of Australians living with CHC was conducted, assessing demographic and disease-related variables, psychosocial characteristics, past experience with psychological support, and psychological support acceptability. The final sample of 156 patients (58 % male) had significantly worse depression, anxiety, stress, and social support than norms. The most acceptable support type was individual psychotherapy (83 %), followed by bibliotherapy (61 %), pharmacotherapy (56 %), online therapy (45 %), and group psychotherapy (37 %). The most prominent predictor of support acceptability was satisfaction with past use. While individual psychotherapy acceptability was encouragingly high, potentially less costly modalities including group psychotherapy or online therapy may be hampered by low acceptability, the reasons for which need to be further explored.
KeywordsHepatitis C Acceptability Mental health Psychotherapy Pharmacotherapy
We would like to thank Nancy Briggs for providing statistical advice, in addition to Megan Phelps, Anton Colman, and Joanne Morgan for their assistance in data collection. The authors alone are responsible for the content and writing of the paper. This research received no specific funding from the public, commercial, or not-for-profit sectors.
Conflict of interest
The authors report no conflicts of interest.
- Australian Bureau of Statistics. (2008). Information paper: An introduction to Socio-Economic Indexes for Areas (SEIFA) 2006. Google Scholar
- Bedossa, P., Bioulac-Sage, P., Callard, P., Chevallier, M., Degott, C., Deugniar, Y., et al. (1994). Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology, 20, 15–20.Google Scholar
- Castera, L., Constant, A., Henry, C., Champbenoit, P., Bernard, P. H., De Ledinghen, V., et al. (2006). Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 24, 1223–1230.CrossRefPubMedGoogle Scholar
- Cuijpers, P., Donker, T., Johansson, R., Mohr, D. C., van Straten, A., & Andersson, G. (2011). Self-guided psychological treatment for depressive symptoms: A meta-analysis. PLoS ONE, 6(6), e21274.Google Scholar
- Evon, D. M., Simpson, K., Kixmiller, S., Galanko, J., Dougherty, K., Golin, C., et al. (2011). A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. American Journal of Gastroenterology, 106(10), 1777–1786.CrossRefPubMedGoogle Scholar
- Gidding, H. F., Topp, L., Middleton, M., Robinson, K., Hellard, M., McCaughan, G., et al. (2009). The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997–2006. Journal of Gastroenterology and Hepatology, 24, 1648–1654.CrossRefPubMedGoogle Scholar
- Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics, 6(2), 65–70.Google Scholar
- Jorm, A. F., Christensen, H., Medway, J., Korten, A. E., Jacomb, P. A., & Rodgers, B. (2000). Public belief systems about the helpfulness of interventions for depression: Associations with history of depression and professional help-seeking. Social Psychiatry and Psychiatric Epidemiology, 35, 211–219.CrossRefPubMedGoogle Scholar
- Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the Depression Anxiety Stress Scales (2nd ed.). Sydney, NSW: Psychology Foundation.Google Scholar
- Martín-Santos, R., Díez-Quevedo, C., Castellví, P., Navinés, R., Miquel, M., Masnou, H., et al. (2008). De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology and Therapeutics, 27, 257–265.CrossRefPubMedGoogle Scholar
- Neri, S., Bertino, G., Petralia, A., Giancarlo, C., Rizzotto, A., Calvagno, G. S., et al. (2010). A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. Journal of Clinical Gastroenterology, 44, e210–e217.CrossRefPubMedGoogle Scholar
- Raison, C. L., Woolwine, B. J., Demetrashvili, M. F., Borisov, A. S., Weinreib, R., Staab, J. P., et al. (2007). Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics, 25, 1163–1174.CrossRefPubMedGoogle Scholar
- Stewart, B. J., Mikocka-Walus, A. A., Harley, H., & Andrews, J. M. (2012). Help-seeking and coping with the psychosocial burden of chronic hepatitis C: A qualitative study of patient, hepatologist, and counsellor perspectives. International Journal of Nursing Studies, 49(5), 560–569.CrossRefPubMedGoogle Scholar
- Swift, J. K., & Callahan, J. L. (2009). The impact of client treatment preferences on outcome: A meta-analysis. Journal of Clinical Psychology, 65(4), 368–381.Google Scholar
- Swift, J. K., Callahan, J. L., & Vollmer, B. M. (2011). Preferences. Journal of Clinical Psychology, 67(2), 155–165.Google Scholar
- The Kirby Institute. (2011). HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2011. Sydney, NSW: The Kirby Institute, The University of New South Wales.Google Scholar